The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer

https://doi.org/10.1016/0277-5379(88)90242-8Get rights and content

Abstract

Eight-eight previously untreated patients with small cell lung cancer were treated with a combination of VP16, adriamycin and vincristine (VPAV) for three courses. Resistance to these drugs is associated with the multidrug resistance (MDR) membrane glycoprotein in cell lines in vitro. The clinical relevance of this mechanism of resistance was assessed by using a second line treatment with intravenous infusions of ifosfamide/mesna 5 g/m2 every 3 weeks in patients with only partial responses or non-responders. Cross-resistance to alkylating agents is rare in the MDR. Ifosfamide produced partial responses in six (43%) of 14 patients unresponsive to prior therapy.

Intravenously infused ifosfamide/mesna was also used in consolidation therapy with only minor bone marrow or urinary tract toxicity. This did not prevent CNS relapse.

The overall response rate to VPAV was 69% and for all treatment modalities, 75%. Median survival for all patients ws 39.5 weeks and 59 weeks for all patients attaining complete response.

The addition of large fraction chest irradiation given with the final course of induction chemotherapy to those with good chemotherapy responses produced a further response in 44% of assessable patients. Combined modality treatment resulted in moderate and reversible toxicity.

The lack of improved survival with ifosfamide and the resistance of the majority of patients to salvage with ifosfamide/mesna suggested that the MDR is not the major mechanism of resistance in the clinic, since cross-resistance to alkylating agents of this type is not a feature of MDR cells.

References (35)

  • S Harland et al.

    A randomized trial of cyclophosphamide pretreatment (‘priming’) before short-duration chemotherapy for small cell lung carcinoma

    Eur J Cancer Clin Oncol

    (1985)
  • W Bakkar et al.

    Combined modality treatment of short duration in small cell lung cancer

    Eur J Cancer Clin Oncol

    (1984)
  • C Marti et al.

    High-dose ifosfamide in advanced osteosarcoma

    Cancer Treat Rep

    (1985)
  • PJ Loehrer et al.

    Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas

    J Clin Oncol

    (1985)
  • H Burkert

    Ifosfamide: European perspective

    Semin Oncol

    (1982)
  • W Scheef et al.

    Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results

    Cancer Treat Rep

    (1975)
  • V Ling et al.

    Multidrug-resistance phenotype in Chinese hamster ovary cells

    Cancer Treat Rep

    (1983)
  • Cited by (41)

    • Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer

      2007, Lung Cancer
      Citation Excerpt :

      Whether the sequence of the regimens used for induction chemotherapy and second-line chemotherapy truly influence the response rates to salvage chemotherapy in SCLC remains to be further evaluated in future studies. Paclitaxel and ifosfamide demonstrated activity as single agents and as part of a combination regimen for SCLC, both in first-line treatment and in the setting of relapsed/refractory disease [19,20,32–37]. The triplet combination of paclitaxel, ifosfamide and platinum analogs were evaluated in several studies.

    • Small cell lung cancer: Biological and therapeutic aspects

      1996, Critical Reviews in Oncology/Hematology
    View all citing articles on Scopus
    View full text